Baxter International Inc. BAX
- Market cap
- $12.2B
- P/E
- 0.0×
Follow BAX
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34.06 | 44.06 | 61.05 | 64.13 | 69.10 | 73.12 | 49.00 | 31.01 | 28.34 | 17.40 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 50.16 | 66.18 | 78.38 | 89.93 | 95.19 | 88.32 | 89.70 | 53.12 | 44.01 | 37.74 |
High Price
|
|||
| 48,000 | 47,000 | 50,000 | 50,000 | 50,000 | 60,000 | 60,000 | 60,000 | 38,000 | 37,500 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| 10,163 | 10,584 | 11,099 | 11,362 | 11,673 | 12,146 | 10,057 | 10,360 | 10,636 | 11,244 |
Revenue
|
|||
| 40.50% | 42.27% | 42.88% | 41.90% | 39.30% | 38.86% | 35.29% | 40.06% | 37.46% | 30.05% |
Gross Margin
|
|||
| 4,954 | 1,100 | 1,617 | 970 | 1,292 | 1,116 | (3,248) | 242 | (289) | (505) |
EBT
|
|||
| 48.75% | 10.39% | 14.57% | 8.54% | 11.07% | 9.19% | (32.30%) | 2.34% | (2.72%) | (4.49%) |
EBT Margin
|
|||
| 4,965 | 602 | 1,546 | 1,011 | 1,110 | 1,295 | (2,421) | 2,663 | (638) | (957) |
Net Income
|
|||
| 800 | 750 | 771 | 820 | 840 | 867 | 4,228 | 984 | 1,472 | 1,756 |
Depreciation
|
|||
| 18.61 | 19.49 | 20.78 | 22.32 | 22.93 | 24.20 | 19.95 | 20.47 | 20.85 | 21.92 |
Revenue/Sh
|
|||
| 9.09 | 1.32 | 3.04 | 1.97 | 2.17 | 2.56 | (4.83) | 5.25 | (1.27) | (1.87) |
Earnings/Sh
|
|||
| 3.03 | 3.16 | 3.78 | 4.13 | 3.67 | 4.43 | 2.40 | 3.41 | 2.00 | 1.65 |
Cash Flow/Sh
|
|||
| (1.32) | (1.13) | (1.23) | (1.37) | (1.39) | (1.38) | (0.75) | (0.85) | (0.87) | (1.00) |
Capex/Sh
|
|||
| 1.71 | 2.02 | 2.54 | 2.77 | 2.28 | 3.05 | 1.65 | 2.56 | 1.12 | 0.65 |
Free CF/Sh
|
|||
| 15.16 | 16.79 | 14.73 | 15.54 | 17.14 | 18.17 | 11.70 | 16.74 | 13.77 | 11.89 |
Book Value/Sh
|
|||
| 546 | 543 | 534 | 509 | 509 | 502 | 504 | 506 | 510 | 513 |
Shares
|
|||
| 4.91 | 50.89 | 21.65 | 41.40 | 37.15 | 33.53 | 0.00 | 7.41 | 0.00 | 0.00 |
PE Ratio
|
|||
| 2.39 | 3.45 | 3.17 | 3.75 | 3.50 | 3.55 | 2.56 | 1.90 | 1.40 | 0.87 |
PS Ratio
|
|||
| 2.93 | 4.00 | 4.47 | 5.38 | 4.68 | 4.72 | 4.36 | 2.32 | 2.12 | 1.61 |
PB Ratio
|
|||
| 2.39 | 3.46 | 3.32 | 3.92 | 3.71 | 4.76 | 4.04 | 2.93 | 2.47 | 1.54 |
EV/Sales
|
|||
| 25.93 | 33.33 | 27.09 | 31.66 | 37.36 | 37.75 | 48.73 | 23.44 | 45.78 | 52.15 |
EV/FCF
|
|||
| 1,654 | 1,714 | 2,017 | 2,104 | 1,868 | 2,222 | 1,211 | 1,726 | 1,019 | 845 |
Op' Cash Flow
|
|||
| (719) | (616) | (659) | (696) | (709) | (691) | (377) | (432) | (446) | (513) |
Capex
|
|||
| 935 | 1,098 | 1,358 | 1,408 | 1,159 | 1,531 | 834 | 1,294 | 573 | 332 |
FCF
|
|||
| 3,830 | 4,442 | 3,145 | 4,273 | 5,078 | 4,636 | 3,266 | 3,097 | 2,342 | 3,902 |
Working Cap'
|
|||
| 2,782 | 3,512 | 3,485 | 5,350 | 6,192 | 17,660 | 16,636 | 13,756 | 13,126 | 9,476 |
Total Debt
|
|||
| (19) | 118 | 1,647 | 2,015 | 2,462 | 14,709 | 14,918 | 10,678 | 11,362 | 7,510 |
Net Debt
|
|||
| 8,280 | 9,116 | 7,866 | 7,912 | 8,726 | 9,121 | 5,895 | 8,468 | 7,024 | 6,102 |
Sh' Equity
|
|||
| 27.20% | 3.69% | 9.42% | 5.90% | 5.77% | 4.80% | (7.87%) | 9.39% | (2.40%) | (4.18%) |
ROA
|
|||
| 5.64% | 8.72% | 10.41% | 11.16% | 9.03% | 3.54% | (8.54%) | 2.31% | 0.05% | (1.41%) |
ROIC
|
|||
| 57.92% | 6.92% | 18.21% | 12.69% | 13.25% | 14.39% | (32.41%) | 36.98% | (8.38%) | (14.58%) |
ROE
|
|||
Baxter International Inc. peers in Medical Instruments & Supplies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| RGEN Repligen Corporation | $10.8B | 253× | Compare |
| COO The Cooper Companies, Inc. | $10.5B | 18.9× | Compare |
| AVTR Avantor, Inc. | $10.4B | 0.0× | Compare |
| ALGN Align Technology, Inc. | $10.4B | 25.5× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SOLV Solventum Corporation | $15.1B | 10.9× | Compare |
| ATR AptarGroup, Inc. | $7.8B | 22.1× | Compare |
| BLCO Bausch + Lomb Corporation | $6.0B | 0.0× | Compare |
| STVN Stevanato Group S.p.A. | $5.8B | 37.7× | Compare |
BAX metrics, ten years each
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
Baxter International Inc. (BAX) key facts
- Baxter International Inc. (BAX) is a Medical Instruments & Supplies company in the Healthcare sector, listed on the New York Stock Exchange.
- Baxter International Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.2 billion, up 5.72% from fiscal 2024.
- As of September 25, 2026, BAX traded at $23.37, a market capitalization of $12.2 billion.
- Baxter International Inc. pays an annual dividend of $1.16 per share, a yield of 2.60%, with a payout ratio of 56.5%.
- Return on equity was −14.6% and debt-to-equity 1.53.
Baxter International Inc. (BAX) Latest News
24 Sep
Baxter International is accelerating portfolio transformation focused on efficiency, connected-care growth and higher-growth units to offset softness in legacy lines. The company aims to simplify its mix—including Kidney Care divestiture—and deploys the Baxter Growth & Performance System to sharpen execution, with hundreds of continuous-improvement events in 2026. Growth engines in Advanced Surgery, Drug Compounding, and Care & Connectivity Solutions are contributing to a favorable mix, while demand for infusion therapies and hospital digitization remains robust in large addressable markets (infusion pumps about $15B; connected-care >$50B). However, near-term hurdles persist: higher manufacturing costs, tariffs and pricing constraints press margins; regulatory and commercial risks around the Novum IQ pump; and China procurement pressures that could drag volumes and pricing. The stock trades as a Zacks Rank #3 (Hold); 2026 sales are expected to rise about 3.3%, with adjusted EPS down around 10% to $2.04. Near-term headwinds (margins, tariffs, Novum IQ, China procurement) could temper upside, while portfolio simplification and growth segments offer modest medium-term upside.
Two volatile stocks for long-term investors and one facing challenges. Baxter International (BAX) is the stock to sell: rolling one-year beta 1.45; core healthcare products include dialysis, IV solutions, and surgical systems. Revenue growth has weakened over the past two years; EPS declined 8.5% annually; returns on capital turned negative. At $23.84, BAX trades about 11.2x forward P/E. Two to buy: Remitly (RELY) and Nubank (NU). RELY benefits from Bezos’s early backing, with 25.8% annual active-customer growth, three-year EPS up 163%, and free cash flow margin widening by 43.1 percentage points; price near $20.35 and forward EV/EBITDA around 9x. NU serves Latin America with 100M+ customers; revenue growth 41.1% over two years, EPS up 48.7%, ROE 15.9%, price around $13.70, forward P/E 14.4x. Full reports available. Declining EPS and weak revenue growth point to a moderate near-term impact on sentiment and stock trajectory.
21 Sep
Baxter International (BAX) is a Deerfield, IL-based healthcare company with an $11.8B market cap that makes products for hemophilia, immune disorders, kidney disease and related conditions. Shares are down 24% from a 52-week high of $30 hit July 30, though they rose about 14.6% in the last quarter and 19.3% year-to-date, outperforming a flat Nasdaq. The stock sits above its 200-day moving average since June but remains below the 50-day MA since September. Key headwinds include a North Carolina manufacturing disruption from severe weather that dented revenue, worse-than-expected earnings and weak full-year guidance, plus cost inflation and high debt servicing squeezing margins. Demand softness for IV solutions and tighter hospital spending weigh on results. Becton, Dickinson (BDX) has outpaced Baxter on the year but also chases growth; analysts keep a Hold rating with a mean target around $27, implying roughly 18% upside. Operational disruptions and earnings volatility threaten margins and near-term sentiment, but growth initiatives and geographic expansion offer counterbalance.
7 Sep
Baxter International Inc. raised its 2026 outlook after strong Q2 growth offset margin pressure. Raised 2026 outlook based on Q2 growth signals major positive shift in long-term performance trajectory.
1 Aug
Baxter International raised its 2026 sales outlook and earnings guidance, driving a 16.8% stock price gain. Raising 2026 guidance signals stronger long-term financial prospects and shifts investor sentiment upward.
Baxter International Inc. (BAX) stock fair value estimate rose after the company beat Q2 expectations and received higher targets. Q2 earnings beat and raised targets prompted an analyst fair value upgrade for Baxter International Inc. (BAX).
Baxter International Inc. (BAX) released Q2 earnings call highlights covering financial results, operational updates and forward guidance. Q2 earnings highlights can moderately shift near-term investor sentiment and stock price but rarely alter long-term company trajectory.
31 Jul
Baxter International Inc. stock rose 19% this week. 19% weekly surge reflects major positive events capable of shifting company trajectory and investor sentiment.
30 Jul
Baxter International Inc. (BAX) shares rose 17% on positive Q2 results. Positive Q2 earnings triggered a 17% share surge that signals major positive effects on future performance and investor sentiment.
Baxter International Inc. reported upbeat Q2 CY2026 results, causing its stock to jump 16.1%. Upbeat quarterly results triggered a 16.1% stock surge showing major positive effect on performance and sentiment.
Baxter International Inc. posted a strong revenue beat in Q2 2026 that offsets other factors during the earnings call. Strong revenue beat in Q2 2026 earnings supports improved short-term investor sentiment for Baxter without altering long-term trajectory.
Baxter International Inc. (BAX) stock rose after Q2 earnings and sales beat forecasts, though margins contracted. Q2 earnings and sales beat offers moderate positive signal for BAX near-term results while margin contraction highlights ongoing cost pressures.
Baxter International Inc. released Q2 earnings results with key financial metrics compared against analyst estimates. Q2 earnings metrics versus estimates directly shape views of Baxter's financial performance and near-term investor sentiment.
Baxter International Inc. (BAX) reported second-quarter 2026 results. Quarterly results update financial performance and may shift near-term investor views.
24 Jul
Baxter International Inc. faces ongoing operational headwinds that may persist into Q2 results and affect financial performance. Expected continuation of operational challenges could moderately influence Baxter's quarterly results and investor sentiment.
23 Jul
Baxter International (BAX) Q2 earnings expected to decline versus prior year. Expected quarterly earnings drop directly signals weaker financial performance that can shift short-term investor views.
8 Jul
Baxter International anticipates Q2 2026 earnings release with analyst projections on revenue, EPS, and segment performance that may shape near-term stock movement. Preview of quarterly earnings can moderately sway short-term sentiment and valuation without altering long-term company trajectory.
19 Jun
Baxter International Inc.'s Synovis MCA unit to lead global rollout of the SHIYA Platform. SHIYA Platform global rollout led by Baxter unit indicates moderate positive effect on product innovation and market reach.
18 Jun
MediThinQ and Synovis Micro Companies Alliance, Inc. announced a strategic global distribution agreement for the SHIYA 3D Visualization Platform to advance microsurgery. Synovis partnership expands Baxter microsurgery offerings with 3D visualization technology that may affect product innovation.
14 Jun
Baxter International (BAX) stock has posted double-digit gains amid ongoing turnaround plans, prompting a fresh valuation assessment. Ongoing turnaround plans may moderately influence Baxter's financial performance and market positioning.
10 Jun
Citi downgrades Baxter International (BAX) citing a tough road ahead for the company. Citi downgrade signals challenges that may affect Baxter's market sentiment and performance.
8 Jun
Baxter's 5008X device could reset demand patterns in home dialysis and materially affect FMS operations. 5008X launch targets core home dialysis segment and could shift Baxter's competitive position and revenue trajectory.
3 May
Baxter International (BAX) beat earnings expectations and reaffirmed its outlook, prompting a valuation reassessment. Earnings beat and reaffirmed outlook signal strong financial health, boosting investor sentiment and stock trajectory.
2 May
Baxter International's Q1 earnings show turnaround progress amid margin pressures, supported by new product launches. Turnaround progress and product launches represent major strategic advancements offsetting margin pressures to significantly shape future performance.
Baxter International (BAX) shares fell 5.2% after reporting a Q1 loss, but the company reaffirmed its full-year turnaround guidance amid questions on operational changes. Q1 loss triggered 5.2% stock drop but reaffirmed turnaround guidance balances the financial impact.
30 Apr
Baxter International Inc. (BAX) released Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, management commentary, and forward guidance. Q1 2026 earnings results, guidance, and strategic insights significantly shape investor sentiment and BAX's market trajectory.
Baxter International Inc. Q1 2026 earnings call summary covers quarterly financial results, operational updates, and forward guidance. Quarterly earnings summaries directly influence financial performance, guidance expectations, and investor sentiment for BAX.
Baxter International (BAX) Q1 earnings key metrics are compared to analyst estimates, highlighting performance in revenue, EPS, and other financial indicators. Q1 earnings metrics versus estimates directly shape investor sentiment and stock trajectory.
Baxter International Inc. (BAX) topped Q1 earnings and revenue estimates. Topping Q1 earnings and revenue estimates boosts investor sentiment and signals strong financial performance with potential for positive stock trajectory.
Baxter International Inc. (BAX) stock rose after Q1 earnings and sales beat expectations, despite margin contraction. Q1 earnings and sales beat positively influenced stock price and financial sentiment, offset somewhat by margin contraction.